Pfizer has filed a lawsuit in Delaware against Metsera and Novo Nordisk, seeking to block Novo’s US$8.5 billion takeover bid for the U.S. obesity drug developer, which Pfizer claims breaches its existing merger agreement.
The pharma giant wants a court order preventing Metsera from terminating their deal and insists the company’s shareholder vote proceed on 13 November.
Pfizer recently secured early antitrust clearance for its own US$7.3 billion acquisition proposal and accuses Novo Nordisk—maker of Wegovy and Ozempic—of trying to suppress competition in the booming obesity drug market.
Novo dismissed the claims as baseless, while Metsera said it would defend its actions in court. The lawsuit highlights intensifying competition for control of emerging “weight-loss therapies” expected to generate billions in future sales.
Image credit: Curated Lifestyle
